U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733908) titled 'Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer' on July 25.
Brief Summary: To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DIAGNOSTIC_TEST: Posluma PET
Posluma(R) (flotufolastat F 18) is an FDA-approved diagnostic PET imaging agent used to detect prostate-specific membrane antigen (PSMA)-positive lesions in men with pr...